Co-developer of Cassava’s potential Alzheimer’s drug cited for ‘egregious misconduct’

Cassava Sciences, a biotech company whose work on the experimental Alzheimer’s drug simufilam has been heavily criticized and is the subject of ongoing federal probes, has suffered another blow.